Patents by Inventor Daniel B. Kim-Shapiro

Daniel B. Kim-Shapiro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170281673
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 5, 2017
    Applicants: The Government of the U.S.A. as represented by the Sec. of the Dept. of Health and Human Services, Loma Linda University, Wake Forest University
    Inventors: Mark T. Gladwin, Alan N. Schechter, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Richard O. Cannon, III
  • Patent number: 9700578
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: July 11, 2017
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Acting through the Louisiana State University Health Sciences Center, The UAB Research Foundation, Loma Linda University, Wake Forest University
    Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
  • Patent number: 9675637
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: June 13, 2017
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting through Louisiana State University Health Sciences Center, The UAB Research Foundation, Loma Linda University, Wake Forest University
    Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Pluta, Edward H. Oldfield, Richard O. Cannon, III
  • Publication number: 20170087181
    Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.
    Type: Application
    Filed: May 4, 2016
    Publication date: March 30, 2017
    Applicants: The Government of the U.S.A. as represented by the Secretary of the Department of Health and Human S, The UAB Research Foundation, Wake Forest University
    Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
  • Patent number: 9387224
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: July 12, 2016
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Wake Forest University, Loma Linda University
    Inventors: Mark T. Gladwin, Alan N. Schechter, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Richard O. Cannon, III
  • Publication number: 20150306183
    Abstract: Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.
    Type: Application
    Filed: July 9, 2015
    Publication date: October 29, 2015
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Wake Forest University
    Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Mauro Tiso
  • Patent number: 9114109
    Abstract: Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: August 25, 2015
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Wake Forest University
    Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Mauro Tiso
  • Publication number: 20150125553
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Application
    Filed: January 5, 2015
    Publication date: May 7, 2015
    Applicants: The Government of the United States of America as represented by the Secretary of the Department of, The Board of Supervisors of Louisiana State Univer and Agricultural and Mechanical College, Acting t, The UAB Research Foundation, Loma Linda University, Wake Forest University
    Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
  • Patent number: 8980871
    Abstract: Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds preferentially react with cell-free OxyHb, as compared to OxyHb encapsulated in a red blood cell, and reacts with MetHb to form iron-nitrosyl Hb or nitrite bound MetHb. It has also been found that such compounds reduce cell-free Hb and hemolysis. Active compounds are also contemplated for use in combination therapies, for example, in combination with the administration of red blood cells and/or an agent that promotes hematopoiesis, or in combination with the administration of a nitric oxide donor.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: March 17, 2015
    Assignees: Wake Forest University Health Sciences, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Daniel B. Kim-Shapiro, S. Bruce King, Daniel A. Sweeney, Mark T. Gladwin
  • Patent number: 8927030
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: January 6, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
  • Publication number: 20140017342
    Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.
    Type: Application
    Filed: September 17, 2013
    Publication date: January 16, 2014
    Applicants: The Government of the United States of America as represented by the Secretary of the Department of, Wake Forest University, University of Alabama at Birmingham
    Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
  • Patent number: 8551536
    Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: October 8, 2013
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, University of Alabama at Birmingham, Wake Forest University
    Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
  • Publication number: 20120195983
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Application
    Filed: February 28, 2012
    Publication date: August 2, 2012
    Inventors: Mark T. Gladwin, Alan N. Schechter, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Richard O. Cannon, III
  • Publication number: 20100323029
    Abstract: Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.
    Type: Application
    Filed: June 16, 2010
    Publication date: December 23, 2010
    Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Mauro Tiso
  • Publication number: 20100247681
    Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.
    Type: Application
    Filed: August 29, 2008
    Publication date: September 30, 2010
    Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
  • Publication number: 20100247682
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Application
    Filed: March 26, 2010
    Publication date: September 30, 2010
    Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
  • Publication number: 20100239692
    Abstract: Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds preferentially react with cell-free OxyHb, as compared to OxyHb encapsulated in a red blood cell, and reacts with MetHb to form iron-nitrosyl Hb or nitrite bound MetHb. It has also been found that such compounds reduce cell-free Hb and hemolysis. Active compounds are also contemplated for use in combination therapies, for example, in combination with the administration of red blood cells and/or an agent that promotes hematopoiesis, or in combination with the administration of a nitric oxide donor.
    Type: Application
    Filed: September 19, 2008
    Publication date: September 23, 2010
    Inventors: Daniel B. Kim-Shapiro, S. Bruce King, Daniel A. Sweeney, Mark T. Gladwin